Use of implantable pacemakers and implantable defibrillators in hypertrophic cardiomyopathy

Area of Science:

• Cardiology
• Electrophysiology
• Cardiovascular Medicine

Background:

• Recent data guide the use of implantable pacemakers and defibrillators in hypertrophic cardiomyopathy (HCM).
• Controlled studies question the efficacy of dual chamber pacemakers for HCM outflow tract obstruction, suggesting a potential placebo effect.
• Previous claims of ventricular hypertrophy regression with chronic pacing lack recent substantiation.

Purpose of the Study:

• To review current data on implantable electronic devices for hypertrophic cardiomyopathy (HCM).
• To evaluate the effectiveness of pacemakers and defibrillators in managing HCM complications.
• To identify risk factors for sudden cardiac death in HCM patients.

Main Methods:

• Review of controlled studies on dual chamber pacing for HCM outflow tract obstruction.
• Analysis of recent reports on risk factors for sudden death in HCM.
• Evaluation of data on implantable defibrillator efficacy in HCM patients with ventricular arrhythmias.

Main Results:

• Dual chamber pacing shows minimal benefit for HCM outflow tract obstruction, with no evidence of hypertrophy regression.
• A normal blood pressure response during exercise may indicate a low risk of sudden death in HCM.
• Sudden cardiac death risk in HCM is directly proportional to the extent of left ventricular hypertrophy.
• Implantable defibrillators are effective in terminating malignant ventricular arrhythmias in HCM.

Conclusions:

• Dual chamber pacemakers are not recommended for outflow tract obstruction in HCM based on current evidence.
• Implantable defibrillators should be considered for HCM patients at significant risk of sudden cardiac death.
• Left ventricular hypertrophy extent and exercise blood pressure response are important prognostic indicators in HCM.